Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2001 December;136(6) > Giornale Italiano di Dermatologia e Venereologia 2001 December;136(6):463-70

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

GUIDELINES   

Giornale Italiano di Dermatologia e Venereologia 2001 December;136(6):463-70

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Guidelines for the use of cyclosporin A in psoriasis. State of the art

Cassano N., Colombo D., Vena G. A.

Università degli Studi di Bari Dipartimento di Clinica Medica, Immunologia e Malattie Infettive Unità di Dermatologia IDI, IRCCS, Roma Istituto Dermopatico dell’Immacolata * Novartis Farma S.p.A., Origgio (VA)


PDF


Several reports have confirmed the therapeutic usefulness of cyclosporin A for the treatment of psoriasis. After almost 15 years of experience, there are many data available as concerns administration, prevention and management of side effects. Considering both these premises and the common use in clinical practice, cyclosporin may be regarded as a first-line approach to psoriasis in eligible patients with severe forms of psoriasis. There is also an increasing trend towards the use of cyclosporine A in less severe forms of psoriasis, which are resistant to topical treatments and deteriorate significantly the quality of life. In these forms a low-dosage intermittent treatment should be preferable, even associated with topical agents if necessary. The use of intermittent treatment regimens offer many advantages, including cost reduction better compliance and better tolerability. Nevertheless, treatment with cyclosporin should be adapted to the single patient and can be influenced by many factors. On the whole, treatment with cyclosporin A is well-tolerated, if the generic recommendations and guidelines are observed. Side effects are commonly of mild intensity and can be controlled by dose adjustment. They fade away after treatment discontinuation. In this work, practical guidelines for use of cyclosporine A will be provided in accordance with recent literature reports and our personal experience, with particular emphasis on patient selection, therapeutic schemes, monitoring and management of side effects.

top of page